[
  {
    "ts": "2025-05-01T16:16:06+00:00",
    "headline": "FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients",
    "summary": "Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients.",
    "url": "https://www.medicaldevice-network.com/news/fda-approves-edwards-tavr-system-for-asymptomatic-aortic-stenosis-patients/",
    "source": "Medical Device Network",
    "provider": "yfinance",
    "raw": {
      "id": "61f44022-f871-35b6-8360-43c9520bd340",
      "content": {
        "id": "61f44022-f871-35b6-8360-43c9520bd340",
        "contentType": "STORY",
        "title": "FDA approves Edwards’ TAVR system for asymptomatic aortic stenosis patients",
        "description": "",
        "summary": "Edwards’ SAPIEN 3 platform becomes the first TAVR system approved by the FDA for asymptomatic severe aortic stenosis patients.",
        "pubDate": "2025-05-01T16:16:06Z",
        "displayTime": "2025-05-01T16:16:06Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/medical_device_network_744/04b66ed4c901184764cfcec7d2e0c80f",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "Edwards Lifesciences currently holds over 60% of the US TAVR market. Image credit: Steve Cukrov via Shutterstock.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SwH2rPEAsuAK1mFppciwmg--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/medical_device_network_744/04b66ed4c901184764cfcec7d2e0c80f.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gqX2ld_0o60cFDFNn3JVQA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/medical_device_network_744/04b66ed4c901184764cfcec7d2e0c80f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Medical Device Network",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.medicaldevice-network.com/news/fda-approves-edwards-tavr-system-for-asymptomatic-aortic-stenosis-patients/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fda-approves-edwards-tavr-system-161606497.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            },
            {
              "symbol": "GLDAF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-05-01T12:00:00+00:00",
    "headline": "Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis",
    "summary": "IRVINE, Calif., May 01, 2025--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.",
    "url": "https://finance.yahoo.com/news/edwards-tavr-receives-fda-approval-120000246.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "370d4c9a-6db4-356c-b313-d66af05af479",
      "content": {
        "id": "370d4c9a-6db4-356c-b313-d66af05af479",
        "contentType": "STORY",
        "title": "Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis",
        "description": "",
        "summary": "IRVINE, Calif., May 01, 2025--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.",
        "pubDate": "2025-05-01T12:00:00Z",
        "displayTime": "2025-05-01T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/5be9a84e359f4f00b3aa2a795aa36e8b",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AOioMKdtIEauDWP_VlJz1Q--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/5be9a84e359f4f00b3aa2a795aa36e8b.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hxKRhic3czb7Jf1GCiXPVA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5be9a84e359f4f00b3aa2a795aa36e8b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edwards-tavr-receives-fda-approval-120000246.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-tavr-receives-fda-approval-120000246.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-05-01T00:03:11+00:00",
    "headline": "Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite?",
    "summary": "We recently published a list of How Did Jim Cramer’s 12 Bold Predictions Play Out?. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other stocks that Jim Cramer recently discussed. During the most recent episode of Mad Money, Jim Cramer revisited the recent turbulence in […]",
    "url": "https://finance.yahoo.com/news/edwards-lifesciences-corporation-ew-jim-000311864.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "ac5dfaee-99e8-3b7c-894b-64c1febdd55f",
      "content": {
        "id": "ac5dfaee-99e8-3b7c-894b-64c1febdd55f",
        "contentType": "STORY",
        "title": "Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite?",
        "description": "",
        "summary": "We recently published a list of How Did Jim Cramer’s 12 Bold Predictions Play Out?. In this article, we are going to take a look at where Edwards Lifesciences Corporation (NYSE:EW) stands against other stocks that Jim Cramer recently discussed. During the most recent episode of Mad Money, Jim Cramer revisited the recent turbulence in […]",
        "pubDate": "2025-05-01T00:03:11Z",
        "displayTime": "2025-05-01T00:03:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/b3057a7754527818c994a28a0dacb15b",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gNoZHNE7bpdyrUEJiEdB1Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/b3057a7754527818c994a28a0dacb15b.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KKxDlh5oXrXWijN0zkO6cA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b3057a7754527818c994a28a0dacb15b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-corporation-ew-jim-000311864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edwards-lifesciences-corporation-ew-jim-000311864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EW"
            },
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]